| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Other Original Articles |
The Nemours Childrens Clinic (R.C.O., E.B.M., J.W., J.E.S.), Jacksonville, Florida 32207; Department of Pediatrics (D.I.S.), All Childrens Hospital, St. Petersburg, Florida 33701; and the University of South Florida College of Medicine, Tampa, Florida 36612
Address all correspondence and requests for reprints to: Robert C. Olney, M.D., The Nemours Childrens Clinic, 807 Childrens Way, Jacksonville, Florida 32207. E-mail: rolney{at}nemours.org
Abstract
The most common cause of congenital adrenal hyperplasia is steroid 21-hydroxylase deficiency. The molecular genetics of this disease are such that genotyping is a potentially useful tool in its diagnosis. An assay was developed using real-time, quantitative PCR to detect deletions of the steroid 21-hydroxylase gene (CYP21A2). This assay was able to detect heterozygous gene deletions with an
error rate of less than 5%, with a power greater than 95%. When combined with allele-specific PCR, genotyping for the nine most common mutations can be completed within hours of blood sampling. This technique was used to study subjects with 21-hydroxylase deficiency in North Florida. Twenty-eight subjects with congenital adrenal hyperplasia, seven first-degree relatives and thirteen normal subjects, were characterized. Of 96 chromosomes, 69 abnormal alleles were identified. Among unrelated abnormal alleles, the frequency of specific mutations was 28% for a gene deletion, 24% for the intron 2 splice mutation, 10% for ile172asn, 8% each for val281leu and the exon 6 cluster, and 6% for gln318x mutations. These frequencies, as well as the genotype/phenotype correlation, were similar to those found in comparable populations. The utility of genotyping in the diagnosis of 21-hydroxylase deficiency is increased by the rapidity of the analysis. With quantitative PCR, the need for more expensive and time consuming Southern blot analysis is reduced and limited to the clarification of certain genotypes. Faster results will allow for more timely initiation of appropriate therapy and limit the exposure of potentially unnecessary therapy.
This article has been cited by other articles:
![]() |
S. Parajes, C. Quinterio, F. Dominguez, and L. Loidi A Simple and Robust Quantitative PCR Assay to Determine CYP21A2 Gene Dose in the Diagnosis of 21-Hydroxylase Deficiency Clin. Chem., September 1, 2007; 53(9): 1577 - 1584. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. E.L.M. Vissers, J. A. Veltman, A. G. van Kessel, and H. G. Brunner Identification of disease genes by whole genome CGH arrays Hum. Mol. Genet., October 15, 2005; 14(suppl_2): R215 - R223. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Keen-Kim, J. B. Redman, R. U. Alanes, M. M. Eachus, R. C. Wilson, M. I. New, J. M. Nakamoto, and R. G. Fenwick Validation and Clinical Application of a Locus-Specific Polymerase Chain Reaction- and Minisequencing-Based Assay for Congenital Adrenal Hyperplasia (21-Hydroxylase Deficiency) J. Mol. Diagn., May 1, 2005; 7(2): 236 - 246. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L Nagpal, Y. Chen, and T. Lin Effects of overexpression of CXCL10 (cytokine-responsive gene-2) on MA-10 mouse Leydig tumor cell steroidogenesis and proliferation J. Endocrinol., December 1, 2004; 183(3): 585 - 594. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Tukel, O. Uyguner, J. Q. Wei, M. Yuksel-Apak, N. Saka, D. X. Song, H. Kayserili, F. Bas, H. Gunoz, R. C. Wilson, et al. A Novel Semiquantitative Polymerase Chain Reaction/Enzyme Digestion-Based Method for Detection of Large Scale Deletions/Conversions of the CYP21 Gene and Mutation Screening in Turkish Families with 21-Hydroxylase Deficiency J. Clin. Endocrinol. Metab., December 1, 2003; 88(12): 5893 - 5897. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |